AI-generated summary
The authors systematically reviewed and meta-analyzed 18 photobiomodulation trials in people with major depressive disorder or clinically significant depressive symptoms. They report a moderate pooled effect on depressive symptoms, with systemic photobiomodulation showing larger effects than transcranial photobiomodulation, and suggest it may be a promising option needing larger trials to establish standardized protocols.
- Studies included
- 18
- Who or what was studied
- Individuals with major depressive disorder or clinically significant depressive symptoms
- Limits stated in the abstract
- The authors note that effectiveness and optimal settings remain unknown and that further large-scale trials are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Although photobiomodulation (PBM) has been investigated as a non-invasive treatment for reducing depressive symptoms, its effectiveness and optimal treatment settings remain unknown. This meta-analysis assessed the overall impact of PBM on depressive symptoms and analyzed significant moderators affecting treatment outcomes.
Methods
We systematically reviewed 18 PBM intervention trials including individuals with major depressive disorder or clinically significant depressive symptoms. Effect sizes (Hedges' g) were pooled, and moderator analyses were conducted using meta-regression and subgroup comparisons. Publication bias was assessed with funnel plots and the trim-and-fill method.
Results
PBM showed a moderate overall effect in reducing depressive symptoms (Hedges' g = -0.47, 95 % CI: -0.73 to -0.22). Importantly, systemic PBM (sPBM) demonstrated significantly larger effects than those of transcranial PBM (tPBM), underscoring their distinct mechanistic and methodological profiles. Laser-based PBM was more effective than LED-based PBM, and longer treatment duration was associated with greater therapeutic benefits, whereas irradiance and treatment frequency were not significant moderators.
Conclusions
PBM appears to be a promising treatment option for depressive symptoms. The clear difference between sPBM and tPBM highlights the need for modality-specific optimization and further large-scale trials to establish standardized therapeutic protocols.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Meta-analysis, Systematic review, Transcranial photobiomodulation, Light-emitting diode, Publication bias, Irradiance, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.